Key result
Combined high CA125 and NT-proBNP linked to ~12-fold higher cardiovascular mortality in acute heart failure.
Why the study?
CA125 is an emerging prognostic biomarker for acute heart failure, prompting evaluation of its utility combined with NT-proBNP for predicting mortality and rehospitalization.
Does the combination of high CA125 and high NT-proBNP levels predict mortality and rehospitalization in patients with acute heart failure?
Cohort (n=316)
No
Does the combination of high CA125 and high NT-proBNP levels predict mortality and rehospitalization in patients with acute heart failure?
Combining CA125 with NT-proBNP significantly improves prognostic prediction for mortality and rehospitalization in patients with acute heart failure.
Answers are grounded in this paper and cite their sources.
CA125 plus NT-proBNP may enhance mortality prediction in AHF; leaves open whether it improves clinical decision-making.
BACKGROUND: Carbohydrate antigen 125 (CA125) is an emerging prognostic biomarker for acute heart failure (AHF). This study aimed to evaluate the prognostic utility of CA125 in combination with N-terminal pro-B-type natriuretic peptide (NT-proBNP) for predicting cardiovascular mortality, all-cause mortality, and a composite outcome of all-cause mortality or rehospitalization due to heart failure in patients with AHF. METHODS: This prospective observational study included 316 patients with AHF. Both CA125 and NT-proBNP levels were measured at the time of first admission. Mortality and rehospitalization due to heart failure were recorded over a 12-month follow-up period. RESULTS: During the follow-up period, 38 patients (12.0%) died from cardiovascular disease, 81 patients (25.6%) died from any cause, and 145 patients (45.9%) experienced either all-cause mortality or rehospitalization due to heart failure. In multivariate Cox regression analyses, the combination of high CA125 and high NT-proBNP levels was associated with increased risks of cardiovascular mortality (adjusted Hazard Ratio [aHR] = 11.77, 95% Confidence Interval [CI]: 3.73-37.09, p < 0.001), all-cause mortality (aHR = 4.53, 95% CI: 1.99-10.28, p < 0.001), and the composite outcome (aHR = 6.02, 95% CI: 2.75-13.24, p < 0.001). The addition of CA125 significantly improved prognostic performance when combined with NT-proBNP. CONCLUSIONS: Both CA125 and NT-proBNP are significant prognostic biomarkers in patients with AHF. The combination of CA125 and NT-proBNP significantly enhances the prediction of cardiovascular mortality, all-cause mortality and the composite outcome of all-cause mortality or rehospitalization due to heart failure in patients with AHF.
No takes yet. Share an insight, caveat, or question.
Truong et al. (2025) conducted a cohort in Acute heart failure (n=316). High CA125 and high NT-proBNP levels vs. Low CA125 and low NT-proBNP levels was evaluated on Cardiovascular mortality (aHR 11.77, 95% CI 3.73-37.09, p=<0.001). The combination of high CA125 and high NT-proBNP levels was associated with a increased risk of cardiovascular mortality compared to low levels of both biomarkers in patients with acute heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: